CN109266610A - A method of promotion Derived from Mesenchymal Stem Cells is neuron - Google Patents
A method of promotion Derived from Mesenchymal Stem Cells is neuron Download PDFInfo
- Publication number
- CN109266610A CN109266610A CN201811095661.1A CN201811095661A CN109266610A CN 109266610 A CN109266610 A CN 109266610A CN 201811095661 A CN201811095661 A CN 201811095661A CN 109266610 A CN109266610 A CN 109266610A
- Authority
- CN
- China
- Prior art keywords
- mesenchymal stem
- cell
- neuron
- culture
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 37
- 210000002569 neuron Anatomy 0.000 title claims abstract description 25
- 210000004027 cell Anatomy 0.000 claims abstract description 53
- 239000002609 medium Substances 0.000 claims abstract description 32
- 230000004069 differentiation Effects 0.000 claims abstract description 27
- 230000001537 neural effect Effects 0.000 claims abstract description 16
- 239000006160 differential media Substances 0.000 claims abstract description 11
- 208000020431 spinal cord injury Diseases 0.000 claims abstract description 9
- 239000001963 growth medium Substances 0.000 claims description 19
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 17
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 17
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 16
- 230000006698 induction Effects 0.000 claims description 14
- 239000012580 N-2 Supplement Substances 0.000 claims description 11
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 11
- 229930002330 retinoic acid Natural products 0.000 claims description 11
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 10
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 10
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 10
- 229930182555 Penicillin Natural products 0.000 claims description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 9
- 229940049954 penicillin Drugs 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 229960005322 streptomycin Drugs 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 5
- 210000003954 umbilical cord Anatomy 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 4
- 238000001976 enzyme digestion Methods 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 239000013049 sediment Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 3
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000249 desinfective effect Effects 0.000 claims description 3
- 229940116977 epidermal growth factor Drugs 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000003855 balanced salt solution Substances 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims 10
- 230000003834 intracellular effect Effects 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 1
- 239000003900 neurotrophic factor Substances 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- 238000012308 immunohistochemistry method Methods 0.000 description 5
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 238000013215 result calculation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1369—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/32—Polylysine, polyornithine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of promotion Derived from Mesenchymal Stem Cells into the method for neuron, comprising the following steps: 1) prepares human mesenchymal stem cell and secondary culture；2) human mesenchymal stem cell after making secondary culture is divided into human mesenchymal stem cell-nerve ball in differential medium；3) human mesenchymal stem cell-nerve ball is made to be divided into neuron in induced medium.Promote neuronotropic differentiation by adding neurotrophic factor in induced medium, the results showed that the cell for expressing mature neural markers object (MAP2ab) and immature neural markers object ('beta '-tubulin III) is significantly increased relative to blank control.Method of the invention provides certain direction for the new treatment of promotion spinal cord injury reparation.
Description
Technical field
It is neuron the present invention relates to technical field of cell culture more particularly to a kind of promotion Derived from Mesenchymal Stem Cells
Method.
Background technique
Spinal cord injury (spinal cord injury, SCI) is a kind of serious cental system illness, after most serious
Fruit is to lead to damage segment with the serious dysfunction of lower limb body, caused by paraplegia patient can be made to lose self-care ability, this is not
Serious body and menticide only are brought to patient, also causes heavy burden to family.
At present in the treatment of patients with spinal cord injury, use generally by means of some drugs and mutually tie with physiotherapy
It closes to slow down the degree of paralysis.But by such treatment, the quality of life of patient is still unable to get good promotion.
How to make the reparation of nervous centralis and reconstruction after spinal cord injury, is currently still a problem.Although refreshing
Discovery through growth factor brings hope to the clinical drug therapy of central nervous system injury, also achieved the effect that it is certain, but
It is that neurotrophy molecular weight of material is too big, blood-brain barrier can not be penetrated and enter central nervous tissue to play its activity.
In spinal cord injury, transplanting may be a kind of practical method for carrying out central nervous system reparation.But it is real
The transplantation treatment of existing cell, it is necessary first to cell differentiation be studied and be assessed at the ability of neuron, and it is thin to develop promotion
The method of born of the same parents' differentiation.
Therefore, those skilled in the art is dedicated to developing a kind of method that promotion stem cell is divided into neuron.
Summary of the invention
To achieve the above object, the present invention provides a kind of promotion Derived from Mesenchymal Stem Cells into the method for neuron.
In a better embodiment of the invention, this method, comprising the following steps:
1) human mesenchymal stem cell and secondary culture are prepared；
2) human mesenchymal stem cell after making secondary culture is divided into human mesenchymal stem cell-in differential medium
Nerve ball；
3) human mesenchymal stem cell-nerve ball is made to be divided into neuron in induced medium.
Preferably, step 3) is specially and smashes human mesenchymal stem cell-nerve ball in step 2), is inoculated into poly-
In L-lysine and the double coated culture vessel containing the induced medium of laminin, in 37 DEG C, 5%CO2Culture
Differentiation 7-10 days.
Further, induced medium is added with 0.5umol/L all-trans retinoic acid, 1%FBS, 5% horse serum, 1%
The NB culture medium of N2 supplement, 1% penicillin/streptomycin and 10ng/mL recombinant human B DNF.
In another preferred embodiment, step 3) is specially by human mesenchymal stem cell-nerve in step 2)
Ball is smashed, and is inoculated into poly-l-lysine and the double coated culture vessel of laminin, is first used first containing BDNF
Induced medium carries out induction differentiation 5-6 days, and the second induced medium containing TGF-β 1 is then used to carry out induction differentiation 4-5
It, cell is in 37 DEG C, 5%CO2Culture.
Further, then after adding the second induced medium containing TGF-β 1, first by cell at 40 DEG C, 5%CO2Middle training
It supports 3-4 hours, is then then transferred to 37 DEG C, 5%CO2Continue culture differentiation 4-5 days.
Further, the first induced medium is added with 0.5umol/L all-trans retinoic acid, 1%FBS, 5% horse blood
Clearly, the NB culture medium of 1%N2 supplement, 1% penicillin/streptomycin and 10ng/mL recombinant human B DNF；Second induced medium
For added with 0.5umol/L all-trans retinoic acid, 1%FBS, 5% horse serum, 1%N2 supplement, 1% penicillin/streptomycin with
And the NB culture medium of 1-5ng/L TGF-β 1.
Further, step 1) is specially to carry out alcohol disinfecting to umbilical cord, and blood vessel is removed in balanced salt solution, and China is logical
Mescenchymal tissue in family name's glue is cut into 0.4-0.6cm3Size, centrifugation obtain mescenchymal tissue part, use serum-free DMEM/
The washing of F12 culture medium；The sediment fraction obtained after washing centrifugation carries out enzymic digestion；Cytometer is carried out to the suspension after enzymic digestion
Number, then carries out inoculated and cultured, i.e. acquisition human mesenchymal stem cell；It is passed when cell grows to 70%-80% fusion rate
Generation.
Preferably, step 2) is carried out using the human mesenchymal stem cell of step 1) forth generation to the 6th generation.
Further, step 2) includes: enzyme process separating step 1) in cultivate human mesenchymal stem cell, and access containing point
Change and is cultivated in the tissue cultures low-adhesion plastic flask of culture medium；Wherein, differential medium is to contain 20ng/ml epidermis
Growth factor, 20ng/mL alkalinity at Porcine HGF and the diluted B27 of 1:50 NB culture medium；Cell is at 37 DEG C, 5%CO2
Lower culture, the fresh epidermal growth factor of addition in every 3-4 days, alkalinity replace once a week differentiation training at Porcine HGF and B27
Support base.
Another aspect of the present invention additionally provide it is a kind of using above-mentioned promotion Derived from Mesenchymal Stem Cells at neuron
Method is studying the application in the neural restoration after spinal cord injury.
Using the method in the present invention, the ratio that Derived from Mesenchymal Stem Cells is neuron can be effectively improved.Using containing
The induced medium of BDNF carries out in the cell after induction differentiation, expresses mature neural markers object (MAP2ab) and immature nerve
The cell proportion of marker ('beta '-tubulin III) has significant raising compared with blank control group, it can respectively reach 8 ±
1.9% and 38.6 ± 2.9%.And use the first induced medium containing BDNF and the second induced medium containing TGF-β 1
In cell after carrying out induction differentiation, mature neural markers object (MAP2ab) and immature neural markers object (β-micro-pipe egg are expressed
White III) cell proportion compared with blank control group, also significantly improve, also, relative to only use containing BDNF induction training
After feeding base carries out induction differentiation, two kinds of positive cell ratios are also further increased.Method of the invention is to promote spinal cord injury
The new treatment of reparation provides certain direction.
It is described further below with reference to technical effect of the attached drawing to design of the invention, specific steps and generation, with
It is fully understood from the purpose of the present invention, feature and effect.
Detailed description of the invention
Fig. 1 is that two kinds of cells occur in the Initial culture of the human mesenchymal stem cell of a preferred embodiment of the invention
Form, Fig. 1 a are strips, and Fig. 1 b is circular.
Fig. 2 is that the human mesenchymal stem cell third generation passage cell culture of a preferred embodiment of the invention is melted to 80%
Cellular morphology when conjunction rate；
Fig. 3 is the human mesenchymal stem cell renewed vaccination of a preferred embodiment of the invention to nerve ball differential medium
Cell after 1-2 days starts the form of aggregation.
Fig. 4 is many drifts of appearance in 3-4 days of the human mesenchymal stem cell of a preferred embodiment of the invention in post-conversion
The sphere of floating cell.
Fig. 5 is the CD44 coloration result in the 3rd generation of the human mesenchymal stem cell of a preferred embodiment of the invention.
Fig. 6 is the nesting for the nerve ball that the human mesenchymal stem cell of a preferred embodiment of the invention is derived
Positive mark's figure.
It is (immature that Fig. 7 is that the human mesenchymal stem cell of a preferred embodiment of the invention is divided into 'beta '-tubulin III
Neural markers object) positive cell Fluorescent immunohistochemistry method result figure.
Fig. 8 is that the human mesenchymal stem cell of a preferred embodiment of the invention is divided into GFAP (astroglia mark
Remember object) positive cell Fluorescent immunohistochemistry method result figure.
Fig. 9 is that the human mesenchymal stem cell of a preferred embodiment of the invention is divided into CalC (oligodendroglia mark
Remember object) positive cell Fluorescent immunohistochemistry method result figure.
Figure 10 is that the human mesenchymal stem cell of a preferred embodiment of the invention is divided into MAP2ab (mature neural markers
Object) positive cell Fluorescent immunohistochemistry method result figure.
Figure 11 is that the human mesenchymal stem cell of a preferred embodiment of the invention is divided into the different neural markers objects positives
The Western blot testing result figure of the GAP-associated protein GAP level of cell.
Specific embodiment
Multiple preferred embodiments of the invention are introduced below with reference to Figure of description, keep its technology contents more clear and just
In understanding.The present invention can be emerged from by many various forms of embodiments, and protection scope of the present invention not only limits
The embodiment that Yu Wenzhong is mentioned.
Experimental method used in the specific embodiment of the invention, if being the method for this field routine without specified otherwise.
Reagent used in the specific embodiment of the invention, if can be obtained by purchase without specified otherwise.
Human mesenchymal stem cell has many advantages of embryonic stem cell and adult stem cell simultaneously, and relative to other
Stem cell, it is advantageous that: plasticity is strong；It is easy to obtain by way of low invasion, and being capable of fast breeding；It is immune
Compatible, the human mesenchymal stem cell of patient oneself can be used for autotransplantation.Therefore, the present invention is using human mesenchymal stem cell
Beginning object carries out differentiation research.
In nerve to occur, microenvironment factor pair proliferation and differentiation have highly important influence.Wherein, BDNF widely divides
Cloth plays the role of in the development, survival and reparation of nerve cell highly important in development and mature nervous system.
This research is by the combination of different trophic factors and different conditions, and observer's Derived from Mesenchymal Stem Cells is at mind
Effect through member.
The preparation of 1 human mesenchymal stem cell of embodiment
Neonatal umbilical cord is obtained, is placed in hanks' balanced salt solution (HBSS, Gibco, USA), 4 DEG C of preservations.Umbilical cord
With alcohol disinfecting 30 seconds of 75%.In HBSS, cord vessels is removed.The mescenchymal tissue being present in magnificent Tong Shi glue is cut
It is cut into about 0.5cm3, and be centrifuged 5 minutes at 1,200rpm.Supernatant, the sediment fraction of mescenchymal tissue are removed after centrifugation
It is washed with serum-free DMEM/F12 culture medium (Gibco, USA), is centrifuged 5 minutes at 1,200rpm later.Sediment fraction uses
0.075%II Collagenase Type (Sigma) at 37 DEG C enzyme process separate 18 hours, then further use 0.125% trypsase/
EDTA (Gibco) digests 30 minutes at 37 DEG C.Suspension uses in the DMEM/F12 progress containing 10% (v/v) fetal calf serum
With the cell in suspension is counted under the microscope.It adjusts to 5-7 × 103A/cm2It is seeded in tissue culture flasks,
In 37 DEG C, 5%CO2Under cultivated, and be maintained at subconfluent state.When cell grows to 70% fusion rate, with the ratio of 1:3
Example carries out secondary culture.Follow-up study is carried out using the cell of forth generation to the 6th generation.
As seen in figure la and lb, in the Initial culture of human mesenchymal stem cell, there are two kinds of cellular morphologies, one is strips
Shape, one is circular.By the passage in three to five generations, the pinacocyte form of single layer is presented in human mesenchymal stem cell, and
And the form of all cells tends to be similar.Fig. 2 shows cellular morphologies when third generation passage cell culture to 80% fusion rate.
2 human mesenchymal stem cell of embodiment forms human mesenchymal stem cell-nerve ball
With 0.125% trypsase/0.02%EDTA separation forth generation human mesenchymal stem cell, the human world after separation is filled
Matter stem cell is with 2 × 105A/cm2Density access tissue cultures low-adhesion plastic flask in, in flask containing differentiation culture
Base.Differential medium be containing 20ng/ml epidermal growth factor (EGF), 20ng/mL alkalinity at Porcine HGF (bFGF) and
The NB culture medium (Invitrogen) of the diluted B27 of 1:50 (Gibco).
Cell is at 37 DEG C, 5%CO2Lower culture.The fresh growth factor of addition in every 3-4 days, replaces once a week culture medium.
It is observed that spherical formed within 4-5 days after trigger differentiation.Before passage, cell is cultivated in differential medium always.
Fig. 3 shows the cellular morphology after human mesenchymal stem cell renewed vaccination to nerve ball differential medium 1-2 days, carefully
Born of the same parents start to assemble, and form human mesenchymal stem cell-nerve ball.The sphere of many floating cells in post-conversion 3-4 days is (i.e. again
7 days or so after inoculation) occur, as shown in Figure 4.
It is passed on enzyme process within every 10-12 days, i.e., adds 0.6% glucose to carry out enzyme process biography using 0.025% trypsase
Generation.Before neuron terminal differentiation, these nerve ball spline structures continue to expand 4-6 week (about 3-4 generation).
The human mesenchymal stem cell in nearly all 3rd generation all shows very strong CD44 dyeing (Fig. 5).It is dry from human mesenchyme
Nerve ball that is cell-derived and coming is confirmed (Fig. 6) by nestin antibody.
The further differentiation (BDNF induction) of embodiment three-occupant apartment mesenchymal stem cells-nerve ball
Collect cultivated in embodiment 2 by human mesenchymal stem cell-nerve ball, and smashed, renewed vaccination to poly-
L-lysine and laminin it is double coated containing induced medium six hole chamber slides (chamber slides,
NUNC in).Cell is in 37 DEG C, 5%CO2Culture differentiation 7-10 days.
Wherein, induced medium be added with 0.5umol/L all-trans retinoic acid (Sigma), 1%FBS, 5% horse serum,
1%N2 supplement, 1% penicillin/streptomycin (being all purchased from Gibco) and 10ng/mL recombinant human B DNF (rhBDNF, R&D
Systems NB culture medium).
In control group, as hereinbefore, only induced medium replaces with the induction training of the control without BDNF to experiment condition
Support base, i.e., it is green added with 0.5umol/L all-trans retinoic acid (Sigma), 1%FBS, 5% horse serum, 1%N2 supplement and 1%
The NB culture medium of mycin/streptomysin (being all purchased from Gibco).
Cell after collecting differentiation is analyzed:
Human mesenchymal stem cell can be divided into that 'beta '-tubulin III (immature neural markers object), (astroglia is thin by GFAP
Born of the same parents' marker), the cell of CalC (oligodendroglia marker) and MAP2ab (mature neural markers object) positive, using immune
The positive cell of different markers is observed by fluorescence histochemical method, as a result as is seen in figs 7-10.Pass through Hoechst
33342+Dyeing, quantifies the cell of the various positives after differentiation, quantitative result calculation method are as follows: corresponding positive cell number
Amount/Hoechst 33342+Quantity × 100% of staining cell, the results are shown in Table 1.
Table 1: the quantitative percentage of positive cell
| Induced medium | 'beta '-tubulin III | GFAP | CalC | MAP2ab |
| Control | 19.2 ± 3.0% | 42.8 ± 3.8% | 27 ± 2% | 4.4 ± 1.8% |
| BDNF induction | 38.6 ± 2.9% | 15.8 ± 4.5% | 20.6 ± 4.6% | 8 ± 1.9% |
The result shows that the 'beta '-tubulin III positive cell and MAP2ab sun that are generated using nerve-specific abductive approach
Property cell be apparently higher than using conventional abductive approach.
Western blot is further verified:
Western blot is conventional method in that art, in this research with for 'beta '-tubulin III (1:500),
A process resistant of MAP2ab (1:500), two process resistant then being connect with peroxidase.Pass through the chemiluminescence method of enhancing
Develop.Use β-Actin (β-Actin) as internal reference.Antibody is all from Chemicon.
The result of Western blot verifying is as shown in figure 11, and result is consistent with ImmunohistochemistryResults Results.
The result shows that expressing mature neural markers object (MAP2ab) and immature neural markers object (β-after adding BDNF
Tubulin III) cell proportion compared with blank control group, have significant raising, that is to say, that be added brain source nerve
Growth factor group significantly improves the ratio that umbilical cord source nerve stem cell transdifferentiation is neuron.
The further differentiation (1 combined induction of BDNF+TGF- β) of 4 human mesenchymal stem cells of embodiment-nerve ball
Collect cultivated in embodiment 2 by human mesenchymal stem cell-nerve ball, and ground, renewed vaccination to poly-
L-lysine and the double coated six hole chamber slide (chamber containing BDNF induced medium of laminin
Slides, NUNC) in.Cell is in 37 DEG C, 5%CO2Culture differentiation 5-6 days.Later, BDNF induced medium is replaced with into TGF-
1 induced medium of β, first at 40 DEG C, 5%CO2Middle culture 3-4 hours, is then then transferred to 37 DEG C, 5%CO2Continue culture differentiation
4-5 days.
Wherein, BDNF induced medium is added with 0.5umol/L all-trans retinoic acid (Sigma), 1%FBS, 5% horse
Serum, 1%N2 supplement, 1% penicillin/streptomycin (being all purchased from Gibco) and 10ng/mL recombinant human B DNF (rhBDNF, R&
D Systems) NB culture medium；
1 induced medium of TGF-β is added with 0.5umol/L all-trans retinoic acid (Sigma), 1%FBS, 5% horse blood
Clearly, the NB culture of 1%N2 supplement, 1% penicillin/streptomycin (being all purchased from Gibco) and 1-5ng/L TGF-β 1 (Sigma)
Base.
In control group, experiment condition as hereinbefore, only all replace by BDNF induced medium and 1 induced medium of TGF-β
It is changed to the control induced medium without BDNF, that is, is added with 0.5umol/L all-trans retinoic acid (Sigma), 1%FBS, 5%
The NB culture medium of horse serum, 1%N2 supplement and 1% penicillin/streptomycin (being all purchased from Gibco).
Cell after collecting differentiation is analyzed:
It is observed, and passed through using positive cell of the Fluorescent immunohistochemistry method to different markers
Hoechst33342+Dyeing, quantifies the cell of the various positives after differentiation, quantitative result calculation method are as follows: corresponding sun
Property cell quantity/Hoechst 33342+Quantity × 100% of staining cell, the results are shown in Table 2.
Table 2: the quantitative percentage of positive cell
The result shows that the 'beta '-tubulin III positive cell and MAP2ab sun that are generated using nerve-specific abductive approach
Property cell be apparently higher than using conventional abductive approach.Also, the method with the independent BDNF induction in embodiment 3, expression are mature
There has also been a degree of for neural markers object (MAP2ab) and the cell proportion of immature neural markers object ('beta '-tubulin III)
It improves.
The preferred embodiment of the present invention has been described in detail above.It should be appreciated that the ordinary skill of this field is without wound
The property made labour, which according to the present invention can conceive, makes many modifications and variations.Therefore, all technician in the art
Pass through the available technology of logical analysis, reasoning, or a limited experiment on the basis of existing technology under this invention's idea
Scheme, all should be within the scope of protection determined by the claims.
Claims (10)
1. a kind of method for promoting Derived from Mesenchymal Stem Cells into neuron, which comprises the following steps:
1) human mesenchymal stem cell and secondary culture are prepared；
2) human mesenchymal stem cell after making secondary culture is divided into human mesenchymal stem cell-nerve in differential medium
Ball；
3) human mesenchymal stem cell-nerve ball is made to be divided into neuron in induced medium.
2. promoting Derived from Mesenchymal Stem Cells at the method for neuron as described in claim 1, which is characterized in that step 3) tool
Body is to smash human mesenchymal stem cell-nerve ball in step 2), is inoculated into poly-l-lysine and laminin double-contracting
In the culture vessel containing the induced medium of quilt, in 37 DEG C, 5%CO2Culture differentiation 7-10 days.
3. promoting Derived from Mesenchymal Stem Cells at the method for neuron as claimed in claim 2, which is characterized in that the induction
Culture medium is added with 0.5umol/L all-trans retinoic acid, 1%FBS, 5% horse serum, 1%N2 supplement, 1% penicillin/chain
The NB culture medium of mycin and 10ng/mL recombinant human B DNF.
4. promoting Derived from Mesenchymal Stem Cells at the method for neuron as described in claim 1, which is characterized in that step 3) tool
Body is to smash human mesenchymal stem cell-nerve ball in step 2), is inoculated into poly-l-lysine and laminin double-contracting
In the culture vessel of quilt, the first induced medium containing BDNF is first used to carry out induction differentiation 5-6 days, then using containing
Second induced medium of TGF-β 1 carries out induction differentiation 4-5 days, and cell is in 37 DEG C, 5%CO2Culture.
5. promoting Derived from Mesenchymal Stem Cells at the method for neuron as claimed in claim 4, which is characterized in that contain in addition
After having the second induced medium of TGF-β 1, first by cell at 40 DEG C, 5%CO2Middle culture 3-4 hours, is then then transferred to 37
DEG C, 5%CO2Continue culture differentiation 4-5 days.
6. promoting Derived from Mesenchymal Stem Cells at the method for neuron as claimed in claim 5, which is characterized in that described first
Induced medium is added with 0.5umol/L all-trans retinoic acid, 1%FBS, 5% horse serum, 1%N2 supplement, 1% mould
The NB culture medium of element/streptomysin and 10ng/mL recombinant human B DNF；Second induced medium is added with 0.5umol/L
All-trans retinoic acid, 1%FBS, 5% horse serum, 1%N2 supplement, 1% penicillin/streptomycin and 1-5ng/L TGF-β 1
NB culture medium.
7. promoting Derived from Mesenchymal Stem Cells at the method for neuron as described in claim 1, which is characterized in that step 1) tool
Body is to carry out alcohol disinfecting to umbilical cord, and blood vessel is removed in balanced salt solution, the mescenchymal tissue in magnificent Tong Shi glue is cut into
0.4-0.6cm3Size, centrifugation obtain mescenchymal tissue part, are washed using serum-free DMEM/F12 culture medium；After washing centrifugation
The sediment fraction of acquisition carries out enzymic digestion；Cell count is carried out to the suspension after enzymic digestion, inoculated and cultured is then carried out, that is, obtains
Obtain human mesenchymal stem cell；It is passed on when cell grows to 70%-80% fusion rate.
8. promoting Derived from Mesenchymal Stem Cells at the method for neuron as described in claim 1, which is characterized in that step 2) is adopted
It is carried out with the human mesenchymal stem cell in step 1) forth generation to the 6th generation.
9. promoting Derived from Mesenchymal Stem Cells at the method for neuron as claimed in claim 8, which is characterized in that step 2) packet
Include: enzyme process separating step 1) in the human mesenchymal stem cell cultivated, and access the low adherency of the tissue cultures containing differential medium
It is cultivated in property plastic flask；Wherein, differential medium is containing 20ng/ml epidermal growth factor, 20ng/mL alkalinity at thin
The NB culture medium of the intracellular growth factor and the diluted B27 of 1:50；Cell is at 37 DEG C, 5%CO2Lower culture, addition in every 3-4 days are fresh
Epidermal growth factor, alkalinity replace once a week differential medium at Porcine HGF and B27.
10. promoting Derived from Mesenchymal Stem Cells at the method for neuron after studying spinal cord injury as described in claim 1
Application in neural restoration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811095661.1A CN109266610B (en) | 2018-09-19 | 2018-09-19 | Method for promoting mesenchymal stem cells to differentiate into neurons |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811095661.1A CN109266610B (en) | 2018-09-19 | 2018-09-19 | Method for promoting mesenchymal stem cells to differentiate into neurons |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109266610A true CN109266610A (en) | 2019-01-25 |
| CN109266610B CN109266610B (en) | 2021-06-25 |
Family
ID=65197675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811095661.1A Active CN109266610B (en) | 2018-09-19 | 2018-09-19 | Method for promoting mesenchymal stem cells to differentiate into neurons |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109266610B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111269887A (en) * | 2020-02-28 | 2020-06-12 | 上海市东方医院（同济大学附属东方医院） | Method for differentiating human pluripotent stem cells to ectoderm |
| CN112899234A (en) * | 2021-04-02 | 2021-06-04 | 中国人民解放军总医院第一医学中心 | Parkinson disease concomitant depression cell model and preparation method and application thereof |
| CN113278624A (en) * | 2021-05-24 | 2021-08-20 | 中山大学·深圳 | Synthetic modified Olig2mRNA and application thereof |
| WO2022257001A1 (en) * | 2021-06-08 | 2022-12-15 | 宁波金未生物科技有限公司 | Method for promoting differentiation of mesenchymal stem cells into neurons and use thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103352026A (en) * | 2013-07-24 | 2013-10-16 | 黑龙江天晴干细胞有限公司 | Method for cultivating autologous umbilical cord mesenchymal stem cells by adopting human umbilical cord blood rich platelet lysate |
| CN104004713A (en) * | 2014-05-14 | 2014-08-27 | 安沂华 | Method for inducing and culturing umbilical cord mesenchymal stem cells into nerve cells |
| CN104419661A (en) * | 2013-08-28 | 2015-03-18 | 中国医学科学院基础医学研究所 | Preparation method of neural stem cell |
| CN104774808A (en) * | 2015-03-27 | 2015-07-15 | 安沂华 | Method for inducible differentiation of umbilical cord mesenchymal stem cells into gamma-aminobutyric acid-ergic neuron |
| CN104789531A (en) * | 2015-03-27 | 2015-07-22 | 安沂华 | Method for inducing umbilical cord mesenchymal stem cells to be differentiated into dopaminergic neurons |
| CN105814196A (en) * | 2013-10-14 | 2016-07-27 | 哈达斯特医疗研究服务和开发有限公司 | Method of obtaining terminally differentiated neuronal lineages and uses thereof |
| WO2017179767A1 (en) * | 2016-04-12 | 2017-10-19 | 서울대학교 산학협력단 | Method for inducing differentiation of adipose stem cells into neural stem cells, neurons and gamma-aminobutyric acid neurons, and method for inducing differentiation of human stem cells that secrete large amounts of growth factors from human bone marrow derived mesenchymal stem cells |
-
2018
- 2018-09-19 CN CN201811095661.1A patent/CN109266610B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103352026A (en) * | 2013-07-24 | 2013-10-16 | 黑龙江天晴干细胞有限公司 | Method for cultivating autologous umbilical cord mesenchymal stem cells by adopting human umbilical cord blood rich platelet lysate |
| CN104419661A (en) * | 2013-08-28 | 2015-03-18 | 中国医学科学院基础医学研究所 | Preparation method of neural stem cell |
| CN105814196A (en) * | 2013-10-14 | 2016-07-27 | 哈达斯特医疗研究服务和开发有限公司 | Method of obtaining terminally differentiated neuronal lineages and uses thereof |
| CN104004713A (en) * | 2014-05-14 | 2014-08-27 | 安沂华 | Method for inducing and culturing umbilical cord mesenchymal stem cells into nerve cells |
| CN104774808A (en) * | 2015-03-27 | 2015-07-15 | 安沂华 | Method for inducible differentiation of umbilical cord mesenchymal stem cells into gamma-aminobutyric acid-ergic neuron |
| CN104789531A (en) * | 2015-03-27 | 2015-07-22 | 安沂华 | Method for inducing umbilical cord mesenchymal stem cells to be differentiated into dopaminergic neurons |
| WO2017179767A1 (en) * | 2016-04-12 | 2017-10-19 | 서울대학교 산학협력단 | Method for inducing differentiation of adipose stem cells into neural stem cells, neurons and gamma-aminobutyric acid neurons, and method for inducing differentiation of human stem cells that secrete large amounts of growth factors from human bone marrow derived mesenchymal stem cells |
Non-Patent Citations (3)
| Title |
|---|
| JUNLIANG等: "Human umbilical cord mesenchymal stem cells derived from Wharton"s jelly differentiate into cholinergic-like neurons in vitro", 《NEUROSCIENCE LETTERS》 * |
| 周志刚等: "人脐带间充质干细胞定向诱导分化成类神经元的实验研究", 《中国病理生理杂志》 * |
| 毕研贞等: "碱性成纤维细胞生长因子与表皮生长因子对神经干细胞增殖与分化的影响", 《中国组织工程研究与临床康复》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111269887A (en) * | 2020-02-28 | 2020-06-12 | 上海市东方医院（同济大学附属东方医院） | Method for differentiating human pluripotent stem cells to ectoderm |
| CN112899234A (en) * | 2021-04-02 | 2021-06-04 | 中国人民解放军总医院第一医学中心 | Parkinson disease concomitant depression cell model and preparation method and application thereof |
| CN113278624A (en) * | 2021-05-24 | 2021-08-20 | 中山大学·深圳 | Synthetic modified Olig2mRNA and application thereof |
| WO2022257001A1 (en) * | 2021-06-08 | 2022-12-15 | 宁波金未生物科技有限公司 | Method for promoting differentiation of mesenchymal stem cells into neurons and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109266610B (en) | 2021-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101748096B (en) | Sub totipotential stem cell and preparation method and application thereof | |
| CN109266610A (en) | A method of promotion Derived from Mesenchymal Stem Cells is neuron | |
| CN104263697B (en) | A kind of method that inducing culture and induction human adipose mesenchymal stem cells generate insulin secretory cell | |
| US11339372B2 (en) | Serum-free medium inducing differentiation of umbilical cord mesenchymal stem cell into insulin-secretion-like cell and preparation method and use thereof | |
| CN102191221A (en) | Neural stem cell capable of self-renewing, preparation method and application thereof | |
| CN103865956B (en) | Utilize the method that recombinant slow virus induced nerve stem cells breaks up to dopaminergic neuron | |
| CN103484432A (en) | Induction medium for inducing neural stem/progenitor cells to be differentiated into oligodendrocyte precursor cells and induction method and application thereof | |
| CN106929470A (en) | It is a kind of for derived mesenchymal stem cells in vitro culture and amplification serum free medium | |
| JP5388297B2 (en) | Adipo cluster | |
| CN107287156A (en) | A kind of isolated culture method of fat mesenchymal stem cell and its application | |
| CN103865873B (en) | The allochthon of Subaerial blue green algae secretion and its application | |
| CN108715831A (en) | Application of the mescenchymal stem cell conditioned medium in the cellular damage for improving cardiomyocytes induced by hypoxia and reoxygenation | |
| CN106282113A (en) | A kind of method utilizing serum-free medium to pass through transdifferentiation acquisition neurocyte | |
| CN109055316A (en) | A kind of building and application of nerve cell and mast cell co-culture system | |
| CN110917217B (en) | Application of muscle stem cells in preparation of anti-inflammatory drugs | |
| CN108865985A (en) | A kind of method of the pre- epithelial-mesenchymal conversion of stem cell source excretion soma | |
| CN105087466B (en) | The culture medium and method that inducing umbilical cord mesenchymal stem breaks up to corneal epithelial cell | |
| CN102747029B (en) | Culture method for retina progenitor cells and culture medium thereof | |
| CN105274049B (en) | A kind of 3D retinas directed differentiation of induction people iPSc sources property is the method for retinal ganglial cells | |
| CN105087475B (en) | A kind of method that cell culture fluid and its application and induction dental pulp stem cell break up to neural-like cells | |
| CN102703380B (en) | Sub-totipotent stem cell, preparation method and application thereof | |
| CN106676056A (en) | Method for inducing differentiation from umbilical cord mesenchymal stem cells to insulin secretion cells | |
| EP4321614A1 (en) | Method for preparing oligodendrocytes and use | |
| CN107058225B (en) | Compound induction culture medium and method for inducing umbilical cord mesenchymal stem cells into neuron-like cells by adopting culture medium | |
| CN113046300B (en) | Culture method for preparing keratinocytes based on differentiation of pluripotent stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240722 Address after: 318014 Building D, building 11, Dream Park, No. 818, east section of Kaifa Avenue, Sanjia street, Taizhou bay new area, Taizhou City, Zhejiang Province Patentee after: Zhejiang Yihe Cell Biotechnology Co.,Ltd. Country or region after: China Address before: No.485 xiangshanhe Road, Dandong Street, Xiangshan County, Ningbo City, Zhejiang Province Patentee before: NINGBO JINWEI BIOTECHNOLOGY Co.,Ltd. Country or region before: China |
|
| TR01 | Transfer of patent right |